Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP18fk0108015)
Received: 15 August 2019
Accepted: 14 October 2020
First Online: 5 November 2020
Ethics approval and consent to participate
: The appropriate research ethics committee granted an exemption of the requirement for ethics review, and deemed that informed consent was not required because the analysis used anonymized records from a pre-existing database.
: Not applicable.
: RK reports his personal lecture fee from Chugai Pharmaceuticals, Japan Vaccine Co Ltd., MSD, Mochida Co Ltd., Roche Diagnostics and BD, and grant for his institute from Chugai Pharmaceuticals, outside the submitted work. He is the Director of the Executive Board Members of the Japanese Expert Board for the Eradication of Cervical Cancer, which has received funding from Qiagen, MSD, Chugai Pharmaceuticals and GlaxoSmithKline, outside the submitted work. Those personal fees and funding have no influence on the manuscript. YO reports personal fees from Statcom, personal fees from Sanofi, grants and personal fees from Eisai, personal fees from Chugai, personal fees from Taiho, personal fees from Shionogi, personal fees from Kowa, non-financial support from Yakult Honsha, non-financial support from Takeda, personal fees from Public Health Research Foundation, personal fees from Daiicchi-Sankyo, outside the submitted work. Those personal fees and funding have no influence on the manuscript. SY, HK, CS and TK declare no competing of interests.